First dedicated leaflet modification solution to enable TAVR in patients at risk of coronary obstruction.
The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback